Trials / Completed
CompletedNCT04546425
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFANTS
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,258 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 42 Days – 112 Days
- Healthy volunteers
- Accepted
Summary
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 20-valent pneumococcal conjugate vaccine | 20-valent pneumococcal conjugate vaccine |
| BIOLOGICAL | 13-valent pneumococcal conjugate vaccine | 13-valent pneumococcal conjugate vaccine |
Timeline
- Start date
- 2020-09-09
- Primary completion
- 2022-04-22
- Completion
- 2023-02-18
- First posted
- 2020-09-14
- Last updated
- 2024-01-08
- Results posted
- 2023-05-15
Locations
66 sites across 12 countries: Australia, Belgium, Czechia, Denmark, Estonia, Finland, Italy, Netherlands, Norway, Poland, Russia, Slovakia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04546425. Inclusion in this directory is not an endorsement.